Redeye comments on Phathom Pharmaceuticals’ recent announcement that the FDA has approved its Citizen Petition, confirming extended market e...
Redeye comments on Cinclus Pharma’s announcement earlier today of a EUR220m licensing agreement with leading European pharmaceutical company...
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Redeye comments on the Q4 report recently published by Cinclus Pharma’s peer, Phathom Pharmaceuticals.
Redeye provides a research update following the Q4 report published by Cinclus earlier today.
Redeye leaves a comment following Cinclus’ announcement of linaprazan glurate having received market approval in China.
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
Redeye leaves a comment following Cinclus’ recent announcement that it has agreed on Paediatric Investigation Plan (PIP) with EMA.
Redeye leaves a short comment following Cinclus’ recent announcement that the manufacturing of the Investigational Medicinal Product (IMP), ...
Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation solution to the USD+5bn GERD treatment mar...
